We Claim:

1. (Original) A clear ibuprofen composition comprising:
   a. from about 15% to about 40% w/w of ibuprofen,
   b. from about 30% to about 70% w/w of polyethylene glycol,
   c. from about 1% to about 10% w/w of a metal carbonate, and
   d. from about 1% to about 10% w/w of water.
2. (Cancelled)
3. (Original) The composition according to claim 1 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.
4. (Cancelled)
5. (Original) The composition according to claim 1 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.
6. (Cancelled)
7. (Original) The composition according to claim 1 further comprising one or more active ingredients, wherein the active ingredients comprise one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.
8. (Original) The composition according to claim 7 wherein the active ingredient comprises pseudoephedrine and pharmaceutically acceptable salts thereof.
9. (Original) The composition according to claim 1 wherein the composition is filled into soft gelatin capsules.
10. (Original) A process of preparing a clear ibuprofen composition, the process comprising the steps of:
    a. dissolving one or more metal carbonates in water to form a solution,

b. adding ibuprofen and the solution of step (a) to polyethylene glycol with optional heating, and

c. stirring to obtain a clear solution.

11. (Cancelled)

12. (Original) The process according to claim 10 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

13. (Cancelled)

14. (Original) The process according to claim 10 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

15. (Cancelled)

16. (Original) The process according to claim 10 further comprising one or more active ingredients, wherein the active ingredients comprise one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

17. (Original) The process according to claim 16 wherein the active ingredient comprises pseudoephedrine and pharmaceutically acceptable salts thereof.

18. (Original) The process according to claim 10 further comprising filling the solution into a soft gelatin capsules.

19. (Original) A soft gelatin capsule of ibuprofen, filled with a clear solution comprising:

a. from about 15% to about 40% w/w of ibuprofen,

b. from about 30% to about 70% w/w of polyethylene glycol,

c. from about 1% to about 10% w/w of a metal carbonate, and

d. from about 1% to about 10% w/w of water.

20. (Original) The soft gelatin capsule of claim 19 wherein gelatin mass of the capsule comprises gelatin, water, plasticizers, coloring agents and preservatives.

21. (Previously Amended) The soft gelatin capsule of claim 20 wherein the plasticizers comprises sorbitol special solution and andrisorb.

22. (Original) The soft gelatin capsule of claim 20 wherein the ratio of gelatin to water varies from 1:0.75 to 1:0.92 and the ratio of gelatin to plasticizer varies from 1:0.35 to 1:0.48.

23. (Original) The soft gelatin capsule according to claim 19 further comprising one or more active ingredients, selected from glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

24. (Original) The soft gelatin capsule according to claim 23 wherein the one or more active ingredient is pseudoephedrine and pharmaceutically acceptable salts thereof.

25. (Cancelled)

26. (Cancelled)

27. (Original) A clear ibuprofen-pseudoephedrine composition comprising:

a. from about 15% to about 40% w/w of ibuprofen,

b. from about 3% to about 6% w/w of pseudoephedrine or a pharmaceutically acceptable salt thereof,

c. from about 30% to about 70% w/w of polyethylene glycol,

d. from about 1% to about 10% w/w of a metal carbonate, and

e. from about 1% to about 10% w/w of water.

28. (Cancelled)

29. (Original) The composition according to claim 27 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

30. (Cancelled)

31. (Original) The composition according to claim 27 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

32. (Cancelled)

33. (Original) The composition according to claim 27 further comprising one or more active ingredients, wherein the active ingredient comprise one or more of glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

34. (Original) The composition according to claim 27 wherein the composition is filled into soft gelatin capsules.

35. (Original) A process of preparing a clear ibuprofen-pseudoephedrine composition comprising the steps of:

a. dissolving one or more metal carbonates in water to form a solution,

a. adding ibuprofen and the solution of step (a) to polyethylene glycol with optional heating,

b. stirring to obtain a clear solution, and

c. adding pseudoephedrine or a pharmaceutically acceptable salt thereof, and stirring to obtain a clear solution.

36. (Original) The process according to claim 35 further comprising filling the solution of step (d) into a soft gelatin capsule.

37. (Cancelled

38. (Cancelled)

39. (Original) A clear ibuprofen composition comprising:

a. from about 15% to about 40% w/w of ibuprofen,

b. from about 30% to about 65% w/w of polyethylene glycol,

c. from about 1% to about 10% w/w of a metal carbonate,

d. from about 1% to about 15% w/w of a surfactant, and

e. from about 1% to about 10% w/w of water.

40. (Cancelled)

41. (Original) The composition according to claim 39 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

42. (Cancelled)

43. (Original) The composition according to claim 39 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

44. (Original) The composition according to claim 39 wherein the surfactant is a non-ionic hydrophilic surfactant.

45. (Original) The composition according to claim 44 wherein the non-ionic hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.

46. (Original) The composition according to claim 39 further comprising one or more active ingredients, wherein the active ingredients comprise one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

47. (Original) The composition according to claim 46 wherein the active ingredient comprises pseudoephedrine and pharmaceutically acceptable salts thereof.

48. (Original) The composition according to claim 39 wherein the composition is filled into soft gelatin capsules.

49. (Original) A process of preparing a clear ibuprofen composition, the process comprising the steps of:

a dissolving one or more metal carbonates in water to form a solution,

b. preparing a solution of one or more surfactants in polyethylene glycol with optional heating,

c. adding ibuprofen and the solution of step (a) to the solution of step (b), and

d. stirring to obtain a clear solution.

50. (Cancelled)

51. (Original) The process according to claim 49 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

52. (Cancelled)

53. (Original) The process according to claim 49 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

54. (Cancelled)

55. (Original) The process according to claim 49 wherein the surfactant comprises a non-ionic hydrophilic surfactant.

56. (Original) The process according to claim 55 wherein the non-ionic hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.

57. (Cancelled)

58. (Cancelled)

59. (Original) A clear ibuprofen-pseudoephedrine composition comprising:

a. from about 15% to about 40% w/w of ibuprofen,

b. from about 3% to about 6% w/w of pseudoephedrine,

c. from about 30% to about 65% w/w of polyethylene glycol,

d. from about 1% to about 10% w/w of a metal carbonate,

e. from about 1% to about 15% w/w of a surfactant, and

f. from about 1% to about 10% w/w of water.

60. (Cancelled)

61. (Original) The composition according to claim 59 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

62. (Cancelled) The composition according to claim 61 wherein the polyethylene glycol has a molecular weight of about 400.

63. (Original) The composition according to claim 59 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

64. (Cancelled)

65. (Original) The composition according to claim 59 wherein the surfactant is a non-ionic hydrophilic surfactant.

66. (Original) The composition according to claim 65 wherein the non-ionic hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.

67. (Original) The composition according to claim 59 further comprising one or more active ingredients, wherein the active ingredients comprise one or more of glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

68. (Original) The composition according to claim 59 wherein the composition is filled into soft gelatin capsules.

69. (Original) A process of preparing a clear ibuprofen-pseudoephedrine composition comprising

the steps of:

a. dissolving one or more metal carbonates in water to form a solution,

b. preparing a solution of one or more surfactants in polyethylene glycol with optional heating,

c. adding ibuprofen and the solution of step (a) to the solution of step (b),

d. stirring to obtain a clear solution, and

e. adding pseudoephedrine or a pharmaceutically acceptable salt thereof to the solution of step (d) with continuous stirring to obtain a clear solution

70. (Cancelled)

71. (Original) The process according to claim 69 wherein the polyethylene glycol has an average molecular weight of about 300 to about 1000.

72. (Original) The process according to claim 69 wherein the metal carbonate comprises one or more of sodium bicarbonate, calcium carbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate, magnesium bicarbonate, or mixtures thereof.

.73. (Original) The process according to claim 69 wherein the surfactant comprises a non-ionic hydrophilic surfactant.

74. (Original) The process according to claim 73 wherein the non-ionic hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.

75. (Original) The process according to claim 69 further comprising one or more active ingredients, wherein the active ingredients comprise one or more of glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts thereof.

1 76. (Original) The process according to claim 69 further comprising filling the
2 solution of step (e) into a soft gelatin capsule.

1 77. (Cancelled)

1 78. (Cancelled)